Using cross-species genetic screening in Drosophila, human cells, and a mouse model, researchers have identified proteins that modulate levels of the mutant ataxin 1 (ATXN1) protein that accumulates in the neurodegenerative disease spinocerebellar ataxia type 1 (SCA1). The proteins, components of the RAS-MAPK-MSK1 pathway, are potential therapeutic targets for the disorder, they said (Park J. Neuron. doi:10.1038/nature12204 [published online May 29, 2013]).
Because the pathway is involved in the early stages of SCA1, targeting it could potentially delay disease development. Indeed, drugs that inhibit different components in the pathway reduced ATXN1 levels and suppressed neurodegeneration in Drosophila and mice.
Hampton T. Potential Targets Found for Neurodegenerative Disease. JAMA. 2013;310(1):22. doi:10.1001/jama.2013.7876
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: